Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Senior Editor Sue Sutter discuss the impact of the departures of several senior leaders in the US Food and Drug Administration’s facility inspection group, Office of Generic Drugs and Office of Prescription Drug Promotion (:26). They also consider Commissioner Martin Makary’s intent to combine the agency’s many adverse event databases (14:52), his idea for a new approval pathway based on a “plausible mechanism” (26:25) and the seemingly increasing influence of politics at the agency despite his declarations that the FDA is apolitical (36:16).
More On These Topics From The Pink Sheet
- US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel
- FDA Leadership Shuffle Continues: Lowell Zeta Returns As OPDP, OGD Leaders Depart
- US FDA’s Makary Floats Vague ‘Plausible Mechanism’ Approval Pathway For Rare Diseases
- US FDA Commissioner Makary Wants To Combine Adverse Event Reporting Systems
- Political Influence And The US FDA: A New Era?
This and other podcasts are available on the Pink Sheet podcast page, as well as the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
